NSU-MD Faculty Articles

Reversal of tumor-mediated immunosuppression.

Publication Title

Clinical cancer research : an official journal of the American Association for Cancer Research

Publisher

American Association for Cancer Research

ISSN

1078-0432

Publication Date

1-15-2007

Keywords

Animals, Antigens, Neoplasm, Cancer Vaccines, Humans, Immune Tolerance, Immunosuppression, Immunotherapy, Mice, Models, Biological, Myeloid Cells, Neoplasms, T-Lymphocytes, T-Lymphocytes, Regulatory, Treatment Outcome

Abstract

Therapeutic cancer vaccines, one form of active immunotherapy, have long been under investigation; consequently, several vaccine-based strategies have now moved from the bench to the clinical arena. Despite their tremendous promise, current vaccine strategies have shown only limited success in clinical settings, even in renal cell carcinoma (RCC), a prototypical malignancy for the application of immunotherapy. There is ample evidence that, especially in RCC, multiple immunosuppressive mechanisms exist that considerably dampen antitumor responses and weaken the activity of current immunotherapeutic regimens. Therefore, it will be necessary to reverse tumor-mediated immunosuppression before immunotherapies can successfully be applied. Recent insights into the nature and characteristics of the regulatory elements of the immune system have provided new opportunities to enhance vaccine-mediated antitumor immunity and, thereby, increase the chance for improving patient outcome. These new insights represent important considerations for the future design and application of more effective cancer vaccines against RCC and other cancers.

DOI

10.1158/1078-0432.CCR-06-1924

Volume

13

Issue

2 Pt 2

First Page

727s

Last Page

732s

Disciplines

Medicine and Health Sciences

Link to Full Text
Peer Reviewed

Find in your library

Share

COinS